Chung-Han Lee Clinical Oncology Society of Australia Annual Scientific Meeting 2020

Abstracts this author is presenting:

• Phase 2 trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): results by independent imaging review and subgroup analyses — Posters